Brokerages Set Cresco Labs Inc. (OTCMKTS:CRLBF) Target Price at $2.50

Shares of Cresco Labs Inc. (OTCMKTS:CRLBF) have earned a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation, two have given a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $2.50.

A number of equities research analysts recently issued reports on CRLBF shares. Cormark downgraded Cresco Labs from a “moderate buy” rating to a “hold” rating in a research report on Monday, November 11th. Roth Capital upgraded shares of Cresco Labs to a “strong-buy” rating in a research report on Sunday, November 10th. Finally, Atb Cap Markets downgraded Cresco Labs from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 9th.

Cresco Labs Stock Performance

OTCMKTS CRLBF opened at $1.13 on Friday. The company’s 50 day simple moving average is $0.95 and its two-hundred day simple moving average is $1.36. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.97 and a quick ratio of 1.39. Cresco Labs has a 1 year low of $0.78 and a 1 year high of $2.64. The stock has a market capitalization of $551.60 million, a PE ratio of -5.65 and a beta of 1.79.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.